ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Ahead of Important Deadline in First Class Action Securities Filed by Firm

New York, New York — (Newsfile Corp. – January 4, 2025) – FOR WHAT: Rosen Law Firm, a global investor rights firm, reminds purchasers of AstraZeneca PLC (NASDAQ: LON: ) securities between February 23, 2022 and December 17, 2024, both dates inclusive ( the “Class Period”), of the February 21, 2025 expiration of the main actor in the securities class action previously filed by the Firm.

SO WHAT: If you purchased AstraZeneca (NASDAQ: ) securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee agreement.

WHAT TO DO NEXT: To join the AstraZeneca class action, go to https://rosenlegal.com/submit-form/?case_id=1331 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information about the class action. A class action lawsuit has already been filed. If you want to serve as the main plaintiff, you must move the Court no later than February 21, 2025. A principal plaintiff is a representative party who acts on behalf of the other members of the class in conducting the litigation.

Why ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, companies issuing notices do not have comparable experience, resources, or significant peer recognition. Many of these firms do not actually litigate securities class actions, but are simply intermediaries who refer clients or partners with law firms that actually litigate cases. Be cautious in selecting counsel. The Rosen Law Firm represents investors around the globe, focusing its practice on securities class actions and shareholder derivative litigation. Rosen Law Firm has obtained the largest securities class action settlement against a Chinese Company at the time. Rosen Law Firm was ranked No. 1 by ISS Securities Class Action (WA:) Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company secured more than $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 Titan of Plaintiffs’ Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, the defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced heightened legal exposure in China, which eventually resulted in the president of AstraZeneca China being arrested by Chinese law enforcement authorities; (3) as a result, AstraZeneca has borne its own legal risks; (4) the foregoing, if disclosed, could materially harm AstraZeneca’s business activities in China; and (5) as a result, the defendants’ statements about their business, operations and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the real details entered the market, the lawsuit claims that investors suffered damages.

To join the AstraZeneca class action, go to https://rosenlegal.com/submit-form/?case_id=1331 call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information about the class action.

No Class has been certified. Until a class is certified, you are not represented by an attorney unless you retain one. You can choose the advice of your choice. You can also be an absent class member and do nothing at this point. The investor’s ability to share in any potential future recovery is not dependent on serving as the principal actor.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https :/ /www.facebook.com/rosenlawfirm.

Attorney Advertising. Previous results do not guarantee a similar result.

——————————–

Contact information:

To view the source version of this press release, visit https://www.newsfilecorp.com/release/236060